6MF0

Crystal Structure Determination of Human/Porcine Chimera Coagulation Factor VIII

6MF0 の概要

• エントリーDOI: 10.2210/pdb6mf0/pdb
• 関連するPDBエントリー: 6MF2
• 分子名称: Coagulation factor VIII chimera, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (9 entities in total)
• 機能のキーワード: hemostasis, hemophilia a, factor viii, chimera, blood clotting
• 由来する生物種: Sus scrofa (Pig); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 342564.29

構造登録者

Smith, I.W.,Spiegel, P.C. (登録日: 2018-09-07, 公開日: 2019-09-11, 最終更新日: 2024-10-23)

主引用文献

Smith, I.W.,d'Aquino, A.E.,Coyle, C.W.,Fedanov, A.,Parker, E.T.,Denning, G.,Spencer, H.T.,Lollar, P.,Doering, C.B.,Spiegel Jr., P.C.
The 3.2 angstrom structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.
J.Thromb.Haemost., 18:57-69, 2020

PubMed Abstract: Coagulation factor VIII represents one of the oldest protein-based therapeutics, serving as an effective hemophilia A treatment for half a century. Optimal treatment consists of repeated intravenous infusions of blood coagulation factor VIII (FVIII) per week for life. Despite overall treatment success, significant limitations remain, including treatment invasiveness, duration, immunogenicity, and cost. These issues have inspired research into the development of bioengineered FVIII products and gene therapies.

PubMed: 31454152
DOI: 10.1111/jth.14621

実験手法

X-RAY DIFFRACTION (3.19999885698 Å)